Oct 6 2011 |
California AB 32's Cap-And-Trade Program Developments |
Sheppard, Mullin, Richter & Hampton LLP |
Jul 2 2021 |
340B Drug Pricing Discount Program Update: HRSA Now Demands That Drug Manufacturers Provide 340B Discounts To Contract Pharmacies Amid Ongoing Litigation |
Sheppard, Mullin, Richter & Hampton LLP |
Sep 29 2021 |
Impact of NYC’s New Delivery Service Data Sharing Requirement |
Sheppard, Mullin, Richter & Hampton LLP |
Apr 18 2022 |
China Proposed Draft Implementing Rules for Human Genetic Resources Management |
Sheppard, Mullin, Richter & Hampton LLP |
May 19 2022 |
FDA White Paper Signals Shift to Performance-Based Reviews of Mature Quality Systems |
Sheppard, Mullin, Richter & Hampton LLP |
Jul 8 2022 |
New Population-Based Option for the Maryland Primary Care Program in 2023 |
Sheppard, Mullin, Richter & Hampton LLP |
Oct 7 2022 |
California Expands Employees’ Right to Off-Duty Cannabis Use |
Sheppard, Mullin, Richter & Hampton LLP |
Oct 12 2015 |
Next Rx: New Medicare Part D Initiative Advances Role of Medication Management in Reform |
Sheppard, Mullin, Richter & Hampton LLP |
Feb 21 2020 |
California Update: New QR Code Certificate Requirements, Uptick in Enforcement Actions, and the Future of California’s Cannabis Regulators |
Sheppard, Mullin, Richter & Hampton LLP |
May 27 2020 |
3D-Printed Masks, Disinfecting Devices, and Simplified Ventilators – a Sampling of Tech Advances in the Age of COVID-19 from California Universities |
Sheppard, Mullin, Richter & Hampton LLP |
Dec 13 2023 |
Federal Circuit Evaluates Impact of the Final Written Decision (FWD) in a Parallel Inter-Partes Review (IPR) on District Court’s decision of Invalidity and Infringement |
Sheppard, Mullin, Richter & Hampton LLP |
Jan 18 2024 |
Federal Circuit Affirms Skinny Label Carve Outs |
Sheppard, Mullin, Richter & Hampton LLP |
Jul 27 2020 |
A Shot Across the Bow of the Pharmaceutical Industry: President Trump Issues a Quartet of Executive Orders on Drug Pricing that Might Eventually (OR NEVER?) Take Effect |
Sheppard, Mullin, Richter & Hampton LLP |
Feb 29 2024 |
District Court Elucidates the Meaning of “to Induce” Under the Federal Health Care Program Anti-Kickback Statute |
Sheppard, Mullin, Richter & Hampton LLP |
Apr 5 2017 |
New York AG Takes Enforcement Action Against Heart Monitoring Apps: Murmurs of Concern are Heard in mHealth App World |
Sheppard, Mullin, Richter & Hampton LLP |
Mar 11 2021 |
DFEH Issues Guidance to Employers Regarding Mandatory COVID-19 Vaccination Policies |
Sheppard, Mullin, Richter & Hampton LLP |
Aug 17 2017 |
Scrambling After an Egg Crisis – EU Safety Guidance for Online Product Sales |
Sheppard, Mullin, Richter & Hampton LLP |
Jun 10 2011 |
Superior Court's Injunction Preventing California's Cap and Trade Program Has Been Stayed...Right? |
Sheppard, Mullin, Richter & Hampton LLP |
Apr 30 2021 |
New York State Legalizes Recreational Marijuana: What Employers Need to Know |
Sheppard, Mullin, Richter & Hampton LLP |
Jun 28 2013 |
Recent Federal and International Developments Good for California Cap and Trade |
Sheppard, Mullin, Richter & Hampton LLP |
Sep 17 2021 |
SAFE Banking Act of 2021: Where Are We on Cannabis Banking Change? |
Sheppard, Mullin, Richter & Hampton LLP |
Dec 13 2021 |
Health Law Policy Heading Into 2022 At The ABA Health Law Summit |
Sheppard, Mullin, Richter & Hampton LLP |
Jan 10 2022 |
CMS’ Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs |
Sheppard, Mullin, Richter & Hampton LLP |
Jan 13 2022 |
Day Three Notes for the 40th Annual J.P. Morgan Healthcare Conference, 2022 |
Sheppard, Mullin, Richter & Hampton LLP |
Apr 12 2022 |
No April Fools: Starting April 1st, Cannabis Operators Face CEQA Compliance Requirements for State Licenses |
Sheppard, Mullin, Richter & Hampton LLP |
Jul 5 2022 |
Recap of AHLA’s Annual Meeting |
Sheppard, Mullin, Richter & Hampton LLP |
Jul 12 2019 |
Regulating E-Cigarettes Remains “Top Priority” For FDA |
Sheppard, Mullin, Richter & Hampton LLP |
Dec 13 2019 |
340B Program-Participating Hospitals Object to CMS’s Proposed Cuts to 340B Program Reimbursement: CMS’s Recent Information Collection Request |
Sheppard, Mullin, Richter & Hampton LLP |
Jun 16 2023 |
DOJ Continues to Discuss Updates to Compliance Program Guidance and Corporate Enforcement Policies |
Sheppard, Mullin, Richter & Hampton LLP |
Oct 17 2023 |
Tele-Prescribing Flexibilities Extended Again in Second Temporary Rule |
Sheppard, Mullin, Richter & Hampton LLP |
Nov 21 2023 |
Voluntary Self-Disclosure of FCPA Violations Following Acquisition Avoids Corruption Charges |
Sheppard, Mullin, Richter & Hampton LLP |
Sep 8 2020 |
New Proposed Regulation Provides More Guidance and Some Relief on Prop 65 Warning Requirements for Heat Processed Foods and Acrylamide |
Sheppard, Mullin, Richter & Hampton LLP |
Sep 14 2020 |
Trade Secret Protection & the COVID-19 Cure: Observations on Federal Policy-Making & Potential Impact on Biomedical Advances |
Sheppard, Mullin, Richter & Hampton LLP |
Apr 18 2024 |
Health-e Law Episode 8: What We Heard at HIMSS 2024 with Michael Orlando & Carolyn Metnick [Podcast] |
Sheppard, Mullin, Richter & Hampton LLP |
Mar 26 2021 |
Online Cannabis Marketplace Businessmen Convicted of Conspiracy to Commit Bank Fraud |
Sheppard, Mullin, Richter & Hampton LLP |
Jan 13 2011 |
New Defense Authorization Act Imposes Buy American Act Mandate for Photovoltaics |
Sheppard, Mullin, Richter & Hampton LLP |
Dec 13 2021 |
Debate Continues Around Scope of Practice Expansion for APPs |
Sheppard, Mullin, Richter & Hampton LLP |
Nov 2 2018 |
OIG Report on Topical Compounded Drug Prescribing, Marketing and Billing Practices Signals Heightened Administrative and Enforcement Scrutiny |
Sheppard, Mullin, Richter & Hampton LLP |
Apr 18 2022 |
Sow What Now?: Cal. Hispanic Chambers of Commerce et. al. v. Ross et. al., The U.S. Supreme Court, and California’s Proposition 12 |
Sheppard, Mullin, Richter & Hampton LLP |
Mar 2 2019 |
The Farm Bill’s Impact on Hemp and CBD – and How Some States are Reacting |
Sheppard, Mullin, Richter & Hampton LLP |
Jul 5 2022 |
CMS Adopts Major Changes to LTC Facility Surveyor Guidance |
Sheppard, Mullin, Richter & Hampton LLP |
Dec 16 2014 |
Sandoz and Celltrion Decline the Invitation to Dance: Biosimilars Challenge the Applicability of the BPCIA’s Exchange Provisions Before Bringing Suit |
Sheppard, Mullin, Richter & Hampton LLP |
Feb 19 2015 |
Go For De Novo: FDA’s Revised Approach to Medical Device Accessories |
Sheppard, Mullin, Richter & Hampton LLP |
Sep 30 2019 |
New Set Of Guidance From FDA Provides Clarity On Digital Health Policies, Machine Learning |
Sheppard, Mullin, Richter & Hampton LLP |
Jun 13 2023 |
Don’t Forget Deception: FTC and Biometrics |
Sheppard, Mullin, Richter & Hampton LLP |
Jul 13 2023 |
The Ninth Circuit Declares that Ambiguity can be Cured with Back Label |
Sheppard, Mullin, Richter & Hampton LLP |
Jul 27 2023 |
FDA Maintains Focus on “Intended Use” for Software-Enabled Medical Devices |
Sheppard, Mullin, Richter & Hampton LLP |
Mar 25 2020 |
Top 10 Questions Asked By Medical Group Clients In Response To COVID-19 |
Sheppard, Mullin, Richter & Hampton LLP |
Nov 10 2023 |
From Good Reprint Practices to SIUU Communications: What Firms Need to Know |
Sheppard, Mullin, Richter & Hampton LLP |
Jun 19 2020 |
Not Today Corona: EEOC Prohibits Testing Employees for Antibodies |
Sheppard, Mullin, Richter & Hampton LLP |